Libtayo(cemiplimab-rwlc)

[indications of libtayo (Ceplimab-RWLC)]

Libtayo (Ceplimab-RWLC) is a PD-1 inhibitor, which is suitable for the treatment of metastatic skin squamous cell carcinoma (CSCC) or locally advanced CSCC patients who cannot receive curative surgery or radiotherapy. This is the first FDA-approved treatment for advanced CSCC and the third anti-PD-1 antibody approved by FDA. Libtayo belongs to PD-(L)1 immunotherapy, and its active pharmaceutical ingredient cemiplimab is a fully humanized monoclonal antibody targeting immune checkpoint PD-1 (programmed cell death protein -1). This drug was created and optimized by Regeneron’s exclusive Velocimmune technology platform, and is currently being developed globally with Sanofi. In addition to CSCC indications, the two sides are also developing other indications of cemiplimab, including basal cell carcinoma (BCC) and first-and second-line treatment of non-small cell lung cancer (NSCLC).

[libtayo (Ceplimab-RWLC) specification]

This product is an injection with a specification of 350mg/7ml.

[administration method of libtayo (Ceplimab-RWLC)]

The recommended dosage is intravenous infusion of 350mg every 3 weeks, and the infusion time should be at least 30 minutes.

[Precautions for Libtayo (Ceplimab-RWLC)]

Developed by Sanofi and Regeneron Pharmaceutical Company, it belongs to PD-1 family and is mainly used for metastatic skin squamous cell carcinoma. Libtayo (Ceplimab-RWLC) is mainly used to treat metastatic skin squamous cell carcinoma (CSCC) or locally advanced CSCC patients who cannot receive curative surgery or radiotherapy. This is the first FDA-approved treatment for advanced CSCC and the third anti-PD-1 antibody approved by FDA. Libtayo belongs to PD-(L)1 immunotherapy, and its active pharmaceutical ingredient cemiplimab is a fully humanized monoclonal antibody targeting immune checkpoint PD-1 (programmed cell death protein -1). This drug was created and optimized by Regeneron’s exclusive Velocimmune technology platform, and is currently being developed globally with Sanofi. In addition to CSCC indications, the two sides are also developing other indications of cemiplimab, including basal cell carcinoma (BCC) and first-and second-line treatment of non-small cell lung cancer (NSCLC).